Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - HCA Healthcare Inc (NYSE:HCA) received a reiterated Market Perform rating and $417.00 price target from Bernstein SocGen Group on Monday. The healthcare giant, with a market capitalization of $104.6 billion, is currently trading near its 52-week high of $439.01. InvestingPro analysis indicates the stock is trading close to its Fair Value.
The healthcare provider reported third-quarter 2025 adjusted EBITDA of $3,870 million, approximately 12% above consensus estimates and 2% above Bernstein’s own forecast. This performance adds to HCA’s impressive track record, with trailing twelve-month EBITDA reaching $14.5 billion and revenue growth of 6.37%.
Following the strong quarterly performance, HCA raised its full-year 2025 guidance, with the company’s volume growth meeting expectations in the third quarter.
Bernstein attributed the EBITDA beat primarily to better-than-expected rate performance, noting that HCA’s strong operating efficiency contributed to the quarterly results.
The research firm indicated that supplemental payments likely impacted the rate-driven earnings growth, and projected this growth lever would slow in 2026 and beyond.
In other recent news, HCA Healthcare reported impressive financial results for the third quarter of 2025. The company exceeded analysts’ expectations with a diluted earnings per share (EPS) of $6.96, compared to the projected $5.72, representing a 21.68% surprise. Revenue also surpassed forecasts, reaching $19.16 billion against the anticipated $18.56 billion. In addition, HCA Healthcare announced plans to offer senior notes through its subsidiary, HCA Inc., with proceeds potentially used for general corporate purposes, including debt repayment. Mizuho has raised its price target for HCA Healthcare to $505, maintaining an Outperform rating, and adjusted its 2025-2027 EBITDA estimates upward by 3%. Meanwhile, Leerink Partners also increased its price target to $470, citing strong third-quarter results and continued demand. These developments highlight ongoing investor interest and confidence in HCA Healthcare’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.